Q-omics provides the consensus-scored HTR4 profile across patient tissues and cancer cell-line models. HTR4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HTR4 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, HTR4 RNA expression shows 12,185 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where HTR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR4 survival associations across molecular data types. HTR4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR4 RNA expression–survival associations across cancer types. High HTR4 expression shows unfavorable associations in THYM and THCA, but favorable associations in BLCA, SKCM, PAAD and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HTR4 RNA expression.
This table summarizes HTR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HTR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR4 shows lower tumor expression in COAD, READ, BRCA, STAD and LUSC and higher tumor expression in LIHC. The COAD box plot shows higher HTR4 RNA expression in normal versus tumor tissue (log2 FC = −1.272, t-test p < 0.001).
This table shows molecular features associated with HTR4 in patient tissues and cancer cell lines. In patient samples, HTR4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
